Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Non Operating Income (2019 - 2026)

ADC Therapeutics has reported Non Operating Income over the past 8 years, most recently at -$7.7 million for Q1 2026.

  • Quarterly results put Non Operating Income at -$7.7 million for Q1 2026, down 3904.43% from a year ago — trailing twelve months through Mar 2026 was -$6.8 million (up 10.38% YoY), and the annual figure for FY2022 was -$31034.0, down 403.81%.
  • Non Operating Income reached -$7.7 million in Q1 2026 per ADCT's latest filing, down from $925000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $22.5 million in Q1 2022 and bottomed at -$48.2 million in Q3 2022.
  • Median Non Operating Income over the past 5 years was $96774.0 (2022), compared with a mean of -$4.0 million.
  • The largest annual shift saw Non Operating Income skyrocketed 321.44% in 2022 before it plummeted 3904.43% in 2026.
  • Over 5 years, Non Operating Income stood at -$9452.0 in 2022, then soared by 9198.6% to $860000.0 in 2023, then surged by 88.84% to $1.6 million in 2024, then plummeted by 43.04% to $925000.0 in 2025, then crashed by 934.92% to -$7.7 million in 2026.
  • Business Quant data shows Non Operating Income for ADCT at -$7.7 million in Q1 2026, $925000.0 in Q3 2025, and -$182000.0 in Q2 2025.